Vifor Pharma AG Logo

Vifor Pharma AG

Global leader in therapies for iron deficiency, anemia, and kidney disease.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen

Description

Vifor Pharma AG, now operating as CSL Vifor, is a global pharmaceutical company that develops, manufactures, and markets products for severe and chronic diseases. It is a global leader in therapies for iron deficiency and iron deficiency anemia, with applications in heart failure, kidney disease, gastroenterology, and women's health. The company also has a strong and growing presence in nephrology, aiming to address the full spectrum of kidney disease through its joint company with Fresenius Medical Care Renal Pharma. Vifor Pharma's business model includes strategic global partnering, in-licensing, and the development of innovative therapies to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

Bone Biologics Corp Logo
Develops a protein-based bone graft substitute for spinal fusion procedures.
United States of America
BBLG
Bonyf N.V. Logo
Develops medical devices for oral, dental, orthodontic, and dermatological care.
Belgium
MLBON
Boryung Corporation Logo
A healthcare company developing pharmaceuticals and investing in health sector innovation.
South Korea
003850
Bosnalijek d.d. Sarajevo Logo
Develops, manufactures, and exports a wide range of pharmaceutical products.
Bosnia and Herzegovina
BSNL
Boule Diagnostics Logo
Provider of hematology systems for decentralized human and veterinary markets.
Sweden
BOUL
Boundless Bio, Inc. Logo
Clinical-stage oncology company targeting ecDNA in oncogene amplified cancers.
United States of America
BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma developing inhibitors for genetically driven cancers.
United States of America
BBOT
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Develops selective serotonin agonists for neurological and psychiatric disorders.
United States of America
DRUG
A clinical-stage biopharma company developing cancer immunotherapies and cell therapies.
Japan
4594

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.